Ilex Medical Ltd (TLV:ILX)
Israel · Delayed Price · Currency is ILS · Price in ILA 6,013.00
-60.00 (-0.99%)
Apr 6, 2026, 2:24 PM IDT
Ilex Medical Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 930.83 | 920.37 | 916.25 | 863.28 | 1,061 | |
Revenue Growth (YoY) | 1.14% | 0.45% | 6.13% | -18.63% | 12.10% |
Cost of Revenue | 718.95 | 704.06 | 689.34 | 580.37 | 681.61 |
Gross Profit | 211.88 | 216.31 | 226.9 | 282.91 | 379.38 |
Selling, General & Admin | 147.98 | 143.77 | 142.6 | 132.77 | 126.84 |
Research & Development | 7.97 | 7.62 | 6.85 | 5.89 | 8.35 |
Other Operating Expenses | -7.56 | 2 | -0.02 | -2.1 | -1.95 |
Operating Expenses | 148.39 | 153.38 | 149.42 | 136.56 | 133.24 |
Operating Income | 63.5 | 62.93 | 77.48 | 146.35 | 246.14 |
Interest Expense | -4.04 | -2.34 | -1.78 | -1.57 | -1.97 |
Interest & Investment Income | - | 7.85 | 5.74 | 1.86 | 1.86 |
Earnings From Equity Investments | -10.63 | -7.19 | -4.01 | -2.69 | -0.26 |
Currency Exchange Gain (Loss) | - | 0.22 | -5.23 | -10.27 | -1.59 |
Other Non Operating Income (Expenses) | 25.3 | -3.74 | -2.78 | -9.84 | 7.4 |
EBT Excluding Unusual Items | 74.14 | 57.73 | 69.43 | 123.85 | 251.58 |
Gain (Loss) on Sale of Investments | - | 4.32 | 4.37 | -2.72 | 3.78 |
Gain (Loss) on Sale of Assets | - | -0.46 | 0.24 | 21.96 | -0.01 |
Pretax Income | 74.14 | 61.6 | 74.04 | 143.09 | 255.35 |
Income Tax Expense | 18.58 | 15.89 | 18.51 | 34.6 | 57.87 |
Earnings From Continuing Operations | 55.56 | 45.7 | 55.53 | 108.49 | 197.48 |
Earnings From Discontinued Operations | - | -6.72 | -4.64 | -6.37 | - |
Net Income to Company | 55.56 | 38.98 | 50.89 | 102.12 | 197.48 |
Net Income | 55.56 | 38.98 | 50.89 | 102.12 | 197.48 |
Net Income to Common | 55.56 | 38.98 | 50.89 | 102.12 | 197.48 |
Net Income Growth | 42.52% | -23.39% | -50.17% | -48.29% | 63.72% |
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 |
Shares Change (YoY) | -0.09% | -0.02% | -0.79% | -0.02% | 5.73% |
EPS (Basic) | 4.97 | 3.48 | 4.55 | 9.05 | 17.51 |
EPS (Diluted) | 4.97 | 3.48 | 4.55 | 9.05 | 17.50 |
EPS Growth | 42.64% | -23.34% | -49.80% | -48.27% | 55.66% |
Free Cash Flow | 45.89 | 51.87 | 31.66 | 43.6 | 229.73 |
Free Cash Flow Per Share | 4.11 | 4.64 | 2.83 | 3.87 | 20.36 |
Dividend Per Share | - | 1.220 | 1.365 | 1.917 | 5.319 |
Dividend Growth | - | -10.63% | -28.80% | -63.97% | - |
Gross Margin | 22.76% | 23.50% | 24.76% | 32.77% | 35.76% |
Operating Margin | 6.82% | 6.84% | 8.46% | 16.95% | 23.20% |
Profit Margin | 5.97% | 4.23% | 5.55% | 11.83% | 18.61% |
Free Cash Flow Margin | 4.93% | 5.64% | 3.46% | 5.05% | 21.65% |
EBITDA | 113 | 96.72 | 111 | 196.39 | 296.63 |
EBITDA Margin | 12.14% | 10.51% | 12.12% | 22.75% | 27.96% |
D&A For EBITDA | 49.5 | 33.79 | 33.52 | 50.04 | 50.49 |
EBIT | 63.5 | 62.93 | 77.48 | 146.35 | 246.14 |
EBIT Margin | 6.82% | 6.84% | 8.46% | 16.95% | 23.20% |
Effective Tax Rate | 25.06% | 25.80% | 25.00% | 24.18% | 22.66% |
Advertising Expenses | - | 3.53 | 3.64 | 3.4 | 1.4 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.